Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Atzpodien

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Acta Haematologica|January 1, 1993
Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivoC Schneekloth, A Körfer, M Hadam, et al.
Oncology|July 1, 1994
Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patientsS Duensing, I Dallmann, J Grosse, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1995
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifenJ Atzpodien, E Lopez Hänninen, H Kirchner, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1996
Cytogenetic studies in renal cell carcinoma patients receiving low-dose recombinant interleukin-2-based immunotherapyS Duensing, E van den Berg-de Ruiter, S Störkel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinomaJ Atzpodien, E Lopez Hänninen, H Kirchner, et al.
British Journal of Cancer|October 29, 1998
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2aR Hoffmann, I Müller, K Neuber, et al.
British Journal of Cancer|April 17, 1999
Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinomaR Hoffmann, A Franzke, J Buer, et al.
The Journal of Investigative Dermatology|October 1, 1993
Conformational polymorphisms of cRNA of T-cell-receptor genes as a clone-specific molecular marker for cutaneous lymphomaM Volkenandt, R Wienecke, O M Koch, et al.
Acta Haematologica|January 1, 1988
Comparative regimens for the ex vivo chemopurification of B cell lymphoma-contaminated marrowS C Gulati, J Atzpodien, A Langleben, et al.
Blood|October 1, 1988
Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeadsC Shimazaki, D Wisniewski, D A Scheinberg, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Acta Haematologica|January 1, 1993
Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivoC Schneekloth, A Körfer, M Hadam, et al.
Oncology|July 1, 1994
Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patientsS Duensing, I Dallmann, J Grosse, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1995
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifenJ Atzpodien, E Lopez Hänninen, H Kirchner, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1996
Cytogenetic studies in renal cell carcinoma patients receiving low-dose recombinant interleukin-2-based immunotherapyS Duensing, E van den Berg-de Ruiter, S Störkel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinomaJ Atzpodien, E Lopez Hänninen, H Kirchner, et al.
British Journal of Cancer|October 29, 1998
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2aR Hoffmann, I Müller, K Neuber, et al.
British Journal of Cancer|April 17, 1999
Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinomaR Hoffmann, A Franzke, J Buer, et al.
The Journal of Investigative Dermatology|October 1, 1993
Conformational polymorphisms of cRNA of T-cell-receptor genes as a clone-specific molecular marker for cutaneous lymphomaM Volkenandt, R Wienecke, O M Koch, et al.
Acta Haematologica|January 1, 1988
Comparative regimens for the ex vivo chemopurification of B cell lymphoma-contaminated marrowS C Gulati, J Atzpodien, A Langleben, et al.
Blood|October 1, 1988
Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeadsC Shimazaki, D Wisniewski, D A Scheinberg, et al.
Pageof 12